Luk Brian T, Fang Ronnie H, Hu Che-Ming J, Copp Jonathan A, Thamphiwatana Soracha, Dehaini Diana, Gao Weiwei, Zhang Kang, Li Shulin, Zhang Liangfang
1. Department of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, U.S.A.
2. Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
Theranostics. 2016 Apr 28;6(7):1004-11. doi: 10.7150/thno.14471. eCollection 2016.
The therapeutic potential of nanoparticle-based drug carriers depends largely on their ability to evade the host immune system while delivering their cargo safely to the site of action. Of particular interest are simple strategies for the functionalization of nanoparticle surfaces that are both inherently safe and can also bestow immunoevasive properties, allowing for extended blood circulation times. Here, we evaluated a recently reported cell membrane-coated nanoparticle platform as a drug delivery vehicle for the treatment of a murine model of lymphoma. These biomimetic nanoparticles, consisting of a biodegradable polymeric material cloaked with natural red blood cell membrane, were shown to efficiently deliver a model chemotherapeutic, doxorubicin, to solid tumor sites for significantly increased tumor growth inhibition compared with conventional free drug treatment. Importantly, the nanoparticles also showed excellent immunocompatibility as well as an advantageous safety profile compared with the free drug, making them attractive for potential translation. This study demonstrates the promise of using a biomembrane-coating approach as the basis for the design of functional, safe, and immunocompatible nanocarriers for cancer drug delivery.
基于纳米颗粒的药物载体的治疗潜力在很大程度上取决于它们在将所载药物安全输送到作用部位的同时规避宿主免疫系统的能力。特别令人感兴趣的是纳米颗粒表面功能化的简单策略，这些策略既本质安全，又能赋予免疫逃避特性，从而延长血液循环时间。在此，我们评估了一种最近报道的细胞膜包覆纳米颗粒平台作为治疗小鼠淋巴瘤模型的药物递送载体。这些仿生纳米颗粒由包裹着天然红细胞膜的可生物降解聚合物材料组成，与传统的游离药物治疗相比，它们能有效地将模型化疗药物阿霉素递送至实体瘤部位，显著增强肿瘤生长抑制作用。重要的是，与游离药物相比，这些纳米颗粒还表现出优异的免疫相容性以及有利的安全性，使其在潜在转化方面具有吸引力。这项研究证明了使用生物膜包覆方法作为设计用于癌症药物递送的功能性、安全且免疫相容的纳米载体基础的前景。
